Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis
Not Applicable
- Conditions
- Idiopathic pulmonary fibrosis
- Registration Number
- JPRN-UMIN000016706
- Lead Sponsor
- Saitama Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion of other clinically known causes of UIP such as drug-induced pneumonitis, collagen vascular diseases, and hypersensitivity pneumonitis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method An absolute change in FVC at week 26 after the initiation of N-acetylcysteine therapy.
- Secondary Outcome Measures
Name Time Method